- Search CSN:
- Members: Login to search all areas
- Not a member? Click here to search public areas
![]() |
Jul 20, 2016 - 1:48 pm
I don't think anyone at the Board has mentioned bieng part of this, but it is important to be aware of, especially members with T-cell issues. max http://www.foxnews.com/health/2016/07/08/juno-cancer-study-halted-after-patient-deaths.html
.
. |
Joined: Nov 2011
Strange demographic - 20
Strange demographic - 20 somethings, and a strange dynamic in the unpredicted and undesireable side effect. I had fludarabine and Cyclophosphamide as conditioning for my transplant (it is SOP at Fred Hutch) and nearly everyone I know maintains that I survived it. This is a huge blow to the trial, but the data, morbid as it is, will certainly help to guide future trials. However, going to a less effective conditioning regimen seems only to guarantee worse overall results. A true catch-22 and sadly, part and parcel of research.